Gene Therapy CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

Gene Therapy manufacturers on CDMO Signal: 61 listed. 9 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Novartis (in-house manufacturer, Signal Score 85.4), Takeda (also makes its own products, Signal Score 83.4) and AGC Biologics (Signal Score 79.9). Outside that set, higher Signal Scores on this list include Pharmaron (Signal Score 86.9), FUJIFILM Diosynth Biotechnologies (Signal Score 86.7) and Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Gene Therapy CDMOs with the most regulatory evidence on file

Novartis
85.4
Basel, Switzerland
17 FDA inspections · 51 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-24 · NAI
See the evidence →
Catalent
76.1
Tampa, FL
24 FDA inspections · 39 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-22 · VAI
Warning letter 2025-11-20
See the evidence →
FUJIFILM Diosynth Biotechnologies
86.7
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
0 FDA inspections · 35 EMA/MHRA GMP certs
Last FDA inspection: None on file
See the evidence →
AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Thermo Fisher Scientific
77.6
Plainville, MA · Alachua, FL · Cambridge, MA
19 FDA inspections · 10 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-30 · NAI
See the evidence →
61
CDMOs tracked
57
Fully scored
22
With FDA records
120
FDA inspections
272
EMA/MHRA GMP certs
2
Warning letters

Gene therapy is delivered through viral vectors — AAV, lentiviral, and adenoviral being the three dominant platforms. AAV dominates in vivo systemic delivery (rare disease, ophthalmology, neurology); lentivirus is the workhorse for ex vivo cell engineering including CAR-T; adenoviral vectors remain relevant for vaccines and select gene therapy programs. Most gene therapy CDMOs specialize in one or two vector platforms, and platform experience is the first filter in any sponsor's shortlist.

The ranking below aggregates every CDMO tracked as a gene therapy manufacturer across these platforms. For platform-specific rankings, use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors evaluating end-to-end programs that combine vector manufacturing with downstream cell processing, the <a href="/modality/cell-and-gene-therapy">cell and gene therapy view</a> extends this list with cell therapy CDMOs.

FDA inspection outcomes across these CDMOs: 46 NAI (no action), 72 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (86), UNITED KINGDOM (55), Denmark (52), Austria (39), Germany (30).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
3
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
4
KB
Durham, NC · Boulder, CO
Hiring · 97+ open roles
84.1 98.5 2 insp · 1 GMP 2026-04-01 · VAI Limited —
5
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
6
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
7
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
8
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
9
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
10
NW
Vilnius, LT; Waltham (MA), USA
Hiring · 16 open roles
80.8 100.0 0 insp · 8 GMP None on file Available —
11
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
12
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
13
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
14
BV
Turku, Finland
Hiring · 2 open roles
79.4 99.8 1 insp · 4 GMP 2024-12-19 · VAI — —
15
UM
Boston, MA
78.7 96.7 2 insp · 0 GMP 2025-12-18 · VAI — —
16
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
17
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
18
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
19
ET
Jumet, BE
78.1 100.0 0 insp · 4 GMP None on file — —
20
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
21
CE
Basel, Switzerland
Hiring · 4 open roles
78.1 100.0 0 insp · 1 GMP None on file — —
22
XP
Bristol, United Kingdom
78.1 100.0 0 insp · 1 GMP None on file — —
23
AD
London, United Kingdom
78.1 100.0 0 insp · 2 GMP None on file — —
24
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
25
AG2
San Carlos, CA
77.6 98.8 1 insp · 0 GMP 2025-04-18 · VAI — —
26
VG
San Sebastián, Spain
Hiring · 3 open roles
76.8 100.0 0 insp · 4 GMP None on file Available —
27
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
28
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
29
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
30
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
31
RT
Rome, IT
Fully evidenced
71.1 100.0 0 insp · 4 GMP None on file — 1 program
32
EM
Baltimore, MD
Also makes its own products
66.1 — — None on file — 4 programs
33
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
34
AN
Columbus, OH
63.0 — — None on file Available —
35
RA
Stockholm, Sweden
63.0 — — None on file — —
36
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
61.8 — — None on file — 10 programs
37
OB
Hamilton, ON
61.5 — 0 insp · 2 GMP None on file — —
38
GF
Alameda, CA and South San Francisco
61.5 — — None on file Available —
39
FB
Columbus, OH
Hiring · 15 open roles
61.2 — — None on file Expanding 3 programs
40
MA
College Station, TX
59.0 — — None on file Available —
41
VB
Philadelphia, PA
59.0 — — None on file — —
42
MS
Princeton, NJ
59.0 — — None on file — —
43
WB
59.0 — — None on file — —
44
EB
Waltham, MA
Hiring · 8 open roles
59.0 — — None on file — —
45
VM
Cambridge, MA
59.0 — — None on file — —
46
AM
Gerenzano, Italy
59.0 — — None on file — —
47
HX
Seoul, KR
Also makes its own products
59.0 — — None on file — —
48
TR
Kusatsu, Shiga Prefecture, Japan
57.9 — — None on file — 8 programs
49
UB
Shanghai, CN · Boston, MA
Hiring · 1 open role
56.5 — — None on file — —
50
CV
Cologne, Germany
56.5 — — None on file — —
—
Germany
Profiled — 2 insp · 2 GMP 2023-09-08 · VAI — —
—
Chongqing, China
Profiled — 1 insp · 0 GMP 2024-03-29 · NAI — —
—
Seal Beach, California, United States
Also makes its own products
Profiled — 3 insp · 0 GMP 2025-10-29 · VAI — —
—
San Diego, California, USA
Profiled — — None on file — —
How we score CDMOs →

What to evaluate in a Gene Therapy CDMO

Vector platform match
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.

Which vector platform does my gene therapy program need?

The three dominant platforms map to distinct program types. AAV is the workhorse for in vivo systemic delivery — rare disease, ophthalmology, neurology, and increasingly cardiac and musculoskeletal indications. It's non-integrating, made at large batch volumes, and dominates approved in vivo gene therapy. Lentiviral vectors are the primary platform for ex vivo cell engineering, including CAR-T and gene-modified HSCs, because they integrate stably into the host genome. Adenoviral vectors retain relevance for vaccines and select gene therapy programs where high transient expression is acceptable. Most CDMOs specialize in one or two platforms rather than all three — filter by platform on the AAV, lentiviral, or adenoviral pages for platform-specific shortlists.

How does CDMO Signal aggregate gene therapy CDMOs?

The gene therapy ranking is a union of CDMOs tagged with any viral-vector platform in our directory (AAV, lentiviral, adenoviral) plus any CDMO tagged directly with "gene therapy". Each CDMO appears once regardless of how many vector platforms they cover — a manufacturer with all three platforms shows up here at their composite Signal Score, and the individual platform pages break out platform-specific rankings. Signal Score is computed identically across all modalities; the aggregation doesn't inflate scores, it just widens the candidate set.

Which gene therapy CDMOs cover multiple vector platforms?

Multi-platform CDMOs — those covering AAV, lentiviral, and often adenoviral — reduce program risk for sponsors evaluating multiple candidates or platforms. Large diversified players like Lonza, Catalent, Thermo Fisher, and Charles River span multiple platforms; specialists like Forge Biologics (AAV-focused) and Andelyn Biosciences deliver depth in one or two. Multi-platform coverage is one buyer signal; regulatory record on the specific target platform is another — the individual profile pages show each CDMO's inspection history and GMP posture at the level of granularity procurement teams need.

How is gene therapy CDMO scoring different from generic biologics?

The Signal Score composition is identical across all modalities, but the underlying data signals mean different things by modality. For gene therapy CDMOs, the Quality pillar (35%) reflects BSL-2 containment history (lentiviral), full/empty capsid analytics posture (AAV), and comparability data across facilities — signals that matter less for generic biologics. The Operations pillar (25%) reflects ClinicalTrials.gov footprint specifically as vector supplier or gene therapy manufacturer, not sponsor-of-record. Sponsors comparing gene therapy CDMOs should read the Signal Score as a starting-point composite and use the individual profile pages for program-specific validation.

Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Gene Therapy CDMOs?
Among Gene Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Novartis, Takeda, AGC Biologics. The table above is the full list. CDMOs cannot pay to change a score.
How many Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 22 Gene Therapy CDMOs with FDA inspection records and 272 EMA/MHRA GMP certificates across the group.
What should I look for in a gene therapy CDMO?
Match the vector platform to your program first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, analytics maturity for that vector type, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific detail.
How many gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of AAV, lentiviral, adenoviral, and generally-tagged gene therapy manufacturers. Each is scored independently on the standard four-pillar Signal Score. CDMOs cannot pay to change a score.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Gene Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Adenoviral Vector CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Cell & Gene Therapy Viral Vector

For a European shortlist, see the best gene therapy CDMO in Europe.